Noxopharm Ltd
ASX:NOX
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Noxopharm Ltd
Net Income
Noxopharm Ltd
Net Income Peer Comparison
Noxopharm Ltd
Glance View
Noxopharm Ltd. engages in the research and development of drugs. The company is headquartered in Gordon, New South Wales. The company went IPO on 2016-08-09. The firm is focused on the treatment of cancer and cytokine release syndrome or septic shock. The firm is engaged in the drug development program, which focuses on the treatment of pancreatic cancer and glioblastoma. The firm's lead drug candidate is called Veyonda (NOX66), which is a therapy developed for chemotherapy and radiotherapy in the treatment of late-stage cancers. Its drug candidate is in Phase II clinical trials. The firm's four pillar oncology program include externally delivered radiation (DARRT) Internally delivered radiation (LuPIN), Checkpoint inhibitors (IONIC) and Chemotherapy (CEP).
See Also
What is Noxopharm Ltd's Net Income?
Net Income
-5.5m
AUD
Based on the financial report for Dec 31, 2025, Noxopharm Ltd's Net Income amounts to -5.5m AUD.
What is Noxopharm Ltd's Net Income growth rate?
Net Income CAGR 5Y
-162%
Over the last year, the Net Income growth was -137%. The average annual Net Income growth rates for Noxopharm Ltd have been 29% over the past three years , -162% over the past five years .
